Effects of flunixin meglumine on cardiopulmonary responses to endotoxin in ponies.

The research article investigates the influence of the drug flunixin meglumine on the heart and lung responses to bacterial toxin (endotoxin) in ponies, finding that the drug counteracts some of the negative effects of the toxin.

Introduction

• The study focuses on the effects of a bacterial toxin, known as endotoxin, on the heart (cardio) and lungs (pulmonary) in ponies. The researchers used flunixin meglumine (FM), a medicine that blocks the activity of an enzyme known as cyclooxygenase.
• Endotoxins, which are components of the outer membrane of certain bacteria like Escherichia Coli, have been recognized for their capacity to trigger diverse illnesses by influencing several bodily functions, including those of the heart and lungs.
• The enzyme cyclooxygenase takes part in the generation of prostanoids, including prostaglandins and thromboxanes, which are involved in inflammation and other physiological functions in the body. By blocking cyclooxygenase, the researchers hypothesized that they could impact the body’s response to the endotoxin.

Methodology

• Anesthetized ponies were intravenously administered with the endotoxin at specific concentrations and durations. Simultaneously, they were breathing a mixture of halothane and 100% oxygen.
• The changes in various cardiopulmonary parameters were gauged at different intervals before and after administering FM, the cyclooxygenase blocking agent.
• These parameters included mean pulmonary arterial pressure (Ppa), pulmonary vascular resistance (PVR), alveolar dead space ventilation (VDA/VT), central plasma volume, cardiac index, hematocrit, and plasma protein concentration.

Results

• Administration of endotoxin led to a rise in the mean pulmonary arterial pressure, pulmonary vascular resistance, and alveolar dead space ventilation, followed by their normalization in about 30 minutes, and followed by another spike in PVR after 5 hours.
• Endotoxin also resulted in a decrease in the central plasma volume and cardiac index and an increase in hematocrit and plasma protein concentration, indicative of a loss of plasma volume.
• All these changes were blocked or significantly reduced by the administration of FM. Furthermore, in ponies treated with FM, the cardiac index even increased, suggesting a stimulatory effect on the heart.

Conclusion

• The study concluded that endotoxin contributes to heart and lung dysfunction in ponies, with some of these effects mediated by cyclooxygenase-dependent metabolites – a process which can be mitigated with the use of Flunixin Meglumine.